Skip to content

Statin therapy for preeclampsia

Statin therapy for preeclampsia - Statin therapy for preeclampsia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000020686
Enrollment
50
Registered
2016-01-22
Start date
2016-02-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preeclampsia

Interventions

administration of statin Participants take pravastatin 10mg per day from diagnosis of preeclampsia to termination. If participants have severe hyperlipemia, they take pravastatin 20mg per day. non-a

Sponsors

Kyoto University Department of Gynecology and Obstetrics
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Patients who have preeclampsia with hyperlipemia.

Exclusion criteria

Exclusion criteria: Unconsented by patients or therapist cyclosporin therapy Past history of rhabdomyolysis Past history of allergic reaction for statins

Design outcomes

Primary

MeasureTime frame
maternal blood pressure, body weight, edema, liver function, kidney function, serum lipids, urinary protein

Secondary

MeasureTime frame
obstetric history, age, postpartum blood pressure, body weight, edema, liver function, kidney function, serum lipids, urinary protein until one week, extend the period of pregnancy, maternal serum soluble fms-like tyrosine kinase 1, maternal serum tumor necrosis factor alfa, maternal urine F2-Isoprostanes

Countries

Japan

Contacts

Public ContactShingo Io

Kyoto University Department of Gynecology and Obstetrics

shinio@kuhp.kyoto-u.ac.jp075-751-3269

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026